Literature DB >> 9779869

Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy.

J Narváez, J Rodriguez-Moreno, M D Martinez-Aguilá, M T Clavaguera.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9779869

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  10 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

Review 2.  Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.

Authors:  L H Calabrese; N N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2006-04-20       Impact factor: 19.103

3.  Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?

Authors:  Gunda Millonig; Michaela Kern; Othmar Ludwiczek; Karin Nachbaur; Wolfgang Vogel
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

4.  Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management.

Authors:  Chun-Jen Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-06-14       Impact factor: 6.047

5.  Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients.

Authors:  Charlie Laohapand; Emvalee Arromdee; Tawesak Tanwandee
Journal:  Hepatol Int       Date:  2015-01-15       Impact factor: 6.047

Review 6.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Authors:  Shunsuke Mori; Shigetoshi Fujiyama
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

7.  Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.

Authors:  Jing Tan; Jingguo Zhou; Pan Zhao; Jing Wei
Journal:  Clin Rheumatol       Date:  2012-04-28       Impact factor: 2.980

8.  Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines?

Authors:  Jinoos Yazdany; Leonard Calabrese
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05       Impact factor: 4.794

Review 9.  Treatment of rheumatic diseases and hepatitis B virus coinfection.

Authors:  Anna Felis-Giemza; Marzena Olesińska; Katarzyna Świerkocka; Ewa Więsik-Szewczyk; Ewa Haładyj
Journal:  Rheumatol Int       Date:  2014-12-31       Impact factor: 2.631

Review 10.  Isolated Anti-HBc: Significance and Management.

Authors:  Florian Moretto; François-Xavier Catherine; Clémentine Esteve; Mathieu Blot; Lionel Piroth
Journal:  J Clin Med       Date:  2020-01-11       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.